Abstract:

Objective To investigate the clinical efficacy and safety of the combination therapy of multi?targeted small molecule tyrosine kinase inhibitors （MTKIs） with immune checkpoint inhibitors （ICIs） for late?stage solid tumor in the patients with failed standard treatment regimens. Methods The patients with advanced solid tumors who had been hospitalized in our hospital from January 2021 to January 2023 after failure of ≥ 2 standard treatment regimens were selected and treated with MTKIs combined with ICIs. The efficacy and safety of this regimen were retrospectively studied. Results A total of 21 patients were included. As of March 1， 2022， the overall population had an ORR of 38%， a DCR of 67%， a median progression free survival （mPFS） of 10 months， and a median survival （mOS） of 15 months. Common adverse reactions were pneumonia and oral ulcers. Conclusion For the patients with advanced solid tumors who have failed standard treatment， MTKIs combined with ICIs may be a treatment option， but prospective studies with a larger sample size are needed to confirm the efficacy and safety of this combination therapy and to explore the population most likely to benefit from this treatment method.

Key words: multi?targeted small molecule tyrosine kinase inhibitor, immunocheckpoint inhibitor, solid tumor, standard treatment protocol